Humulin Regular

Humulin Regular is a short‑acting insulin human (rDNA) product supplied as a sterile injection solution for subcutaneous use. It contains recombinant human insulin as the active ingredient and is marketed in the European Union as a prescription‑only medication. The formulation is designed to provide rapid glucose‑lowering effects after injection, supporting the management of diabetes mellitus.

Humulin Regular is indicated for the control of blood glucose in patients with diabetes mellitus. It is used as part of a comprehensive diabetes management plan that may include diet, exercise, and other antidiabetic agents.

- Treatment of type 1 diabetes mellitus in adults, adolescents, and children. - Management of type 2 diabetes mellitus when oral agents are insufficient. - Use in hospital settings for rapid correction of hyperglycemia. - Adjunct therapy during pregnancy or lactation when insulin is required. - Pre‑meal dosing to cover carbohydrate intake and prevent post‑prandial spikes. - Adjustment of basal insulin regimens in patients requiring tighter glycemic control.

Humulin Regular may cause a range of adverse reactions, ranging from mild to severe. Awareness of these potential effects helps patients and clinicians monitor therapy safely.

Common: - Hypoglycemia (low blood glucose) - Injection site redness, swelling, or itching - Lipodystrophy at the injection site - Weight gain - Mild nausea or abdominal discomfort

Serious: - Severe hypoglycemia with loss of consciousness or seizures - Allergic reactions such as rash, urticaria, or anaphylaxis - Edema or heart failure exacerbation in susceptible individuals - Persistent hyperglycemia indicating possible insulin resistance or dosing issues

Before initiating Humulin Regular, several safety considerations should be reviewed to minimize risk.

- Assess renal and hepatic function, as impairment can alter insulin clearance. - Monitor for signs of hypoglycemia, especially in patients with irregular meals or increased physical activity. - Use caution in patients with cardiovascular disease, as rapid glucose shifts may affect cardiac stability. - Adjust doses during pregnancy, lactation, or in the elderly, who may have altered insulin sensitivity. - Educate patients on proper injection technique to avoid lipohypertrophy. - Review concomitant use of other glucose‑lowering agents to prevent additive hypoglycemic effects.

Humulin Regular can interact with various medications, influencing its efficacy or safety profile.

Avoid: - Other insulin products or concentrated insulin formulations that may cause overlapping dosing. - Beta‑blockers, which can mask hypoglycemia symptoms. - High‑dose salicylates that may potentiate insulin’s glucose‑lowering effect.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - ACE inhibitors or ARBs, which may enhance insulin sensitivity. - Corticosteroids, which can raise blood glucose and require dose adjustments. - Thiazide diuretics, which may affect glucose metabolism. - Alcohol, as it can cause unpredictable glucose fluctuations.